Vitrolife publishes prospectus in connection with the admission to trading on Nasdaq Stockholm due to non-cash issue

Rhea-AI Summary

Vitrolife AB has announced a prospectus for the trading of newly issued shares on Nasdaq Stockholm. This follows a non-cash issue to acquire all shares in Mendel Holdco S.L., and indirectly in Igenomix S.L.. The total number of shares will rise by 17,251,312, increasing the share capital to SEK 27,631,226.760. Existing shareholders will experience a 12.7% dilution of their capital and votes. The prospectus is now available from the Swedish Financial Supervisory Authority and the company’s website.

Positive

• None.

Negative

• Existing shareholders face a 12.7% dilution of capital and votes.

GOTHENBURG, Sweden, Nov. 26, 2021 /PRNewswire/ -- Vitrolife AB (publ) ("Vitrolife") publishes a prospectus for the admission to trading of newly issued shares in Vitrolife on Nasdaq Stockholm's main market in connection with a non-cash issue through which Vitrolife acquires all shares in Mendel Holdco S.L. and thereby indirectly all shares in Igenomix S.L. ("Igenomix") ("The Transaction"). The transaction is described in more detail in Vitrolife's press release dated 8 July 2021. The prospectus does not contain any offer to subscribe for, or in any other way acquire shares or other financial instruments in Vitrolife, either in Sweden or in any other jurisdiction.

The transaction means that the number of shares in Vitrolife will increase by 17,251,312 shares from 118,195,878 shares to a total of 135,447,190 shares and that the share capital will increase by SEK 3,519,267.648, from SEK 24,111,959.112 to a total of SEK 27,631,226.760. The dilution for Vitrolife's existing shareholders amounts to 12.7 percent of capital and votes.

The prospectus, that has been prepared in connection with the admission to trading of the newly issued shares, has today been approved and registered by the Swedish Financial Supervisory Authority ("Finansinspektionen"). The prospectus is available on Finansinspektionen's website, www.fi.se, and Vitrolife's website, www.vitrolife.com, as well as on request in paper format.

Appendix: Prospectus (Swedish)

Gothenburg, November 26, 2021

VITROLIFE AB (publ)

Thomas Axelsson, CEO

Queries should be addressed to:

Thomas Axelsson, CEO, tel 46 31 721 80 01

Mikael Engblom, CFO, tel 46 31 721 80 14

The information was submitted for publication, through the agency of the contact person set out above, at 11.00 am CET on November 26, 2021.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/vitrolife-ab--publ-/r/vitrolife-publishes-prospectus-in-connection-with-the-admission-to-trading-on-nasdaq-stockholm-due-t,c3461400

The following files are available for download:

https://mb.cision.com/Main/1031/3461400/1502136.pdf

Prospekt Vitrolife AB.PDF

View original content:https://www.prnewswire.com/news-releases/vitrolife-publishes-prospectus-in-connection-with-the-admission-to-trading-on-nasdaq-stockholm-due-to-non-cash-issue-301432331.html

SOURCE Vitrolife AB (publ)

FAQ

What is the recent share dilution for Vitrolife AB?

Vitrolife AB's recent share dilution is 12.7% for existing shareholders.

What acquisition is Vitrolife AB pursuing?

Vitrolife AB is acquiring all shares in Mendel Holdco S.L. and indirectly in Igenomix S.L..

When was the prospectus for Vitrolife AB approved?

The prospectus for Vitrolife AB was approved on November 26, 2021.

How many new shares will Vitrolife AB issue?

Vitrolife AB will issue 17,251,312 new shares.

What will be the new share capital of Vitrolife AB?

The new share capital of Vitrolife AB will be SEK 27,631,226.760.